PCSK9 and venous thromboembolism: A post hoc analysis of the FOURIER trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects With Elevated Risk) suggested that an increased risk of venous thromboembolism (VTE) was significantly related to the increased Lp (a) but not LDL-C levels (32).